News Details Page

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has entered

Automating Wilson Wolf's G-Rex® bioreactors with Multiply Labs' robotic technology is driven by a mutual goal to standardize, simplify, and reduce costs for cell and gene-modified therapy manufacturing a robotics company developing industry-leading automated manufacturing

The G-Rex® Grant Program will provide academic and commercial institutions engaged in IND enabling pre-clinical research, process development, and/or ongoing GMP manufacturing of cell and gene therapies with the material resources and services needed to implement